| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5656722 | SANOFI AVENTIS US | A21 -, B30 - modified insulin derivatives having an altered action profile |
Aug, 2014
(9 years ago) | |
|
US5656722 (Pediatric) | SANOFI AVENTIS US | A21 -, B30 - modified insulin derivatives having an altered action profile |
Feb, 2015
(9 years ago) | |
| US7713930 | SANOFI AVENTIS US | Acidic insulin preparations having improved stability |
Jun, 2023
(10 months ago) | |
| US7476652 | SANOFI AVENTIS US | Acidic insulin preparations having improved stability |
Jul, 2023
(9 months ago) | |
|
US7713930 (Pediatric) | SANOFI AVENTIS US | Acidic insulin preparations having improved stability |
Dec, 2023
(4 months ago) | |
|
US7476652 (Pediatric) | SANOFI AVENTIS US | Acidic insulin preparations having improved stability |
Jan, 2024
(3 months ago) | |
| US7918833 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2027
(3 years from now) | |
|
US7918833 (Pediatric) | SANOFI AVENTIS US | Pen-type injector |
Mar, 2028
(3 years from now) | |
Lantus is owned by Sanofi Aventis Us.
Lantus contains Insulin Glargine Recombinant.
Lantus has a total of 8 drug patents out of which 6 drug patents have expired.
Expired drug patents of Lantus are:
- US5656722
- US5656722*PED
- US7713930
- US7476652
- US7713930*PED
- US7476652*PED
Lantus was authorised for market use on 27 April, 2007.
Lantus is available in injectable;injection dosage forms.
Lantus can be used as treatment of diabetes mellitus.
The generics of Lantus are possible to be released after 23 March, 2028.
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Treatment of diabetes mellitus
Dosage: INJECTABLE;INJECTION
LANTUS family patents
